Funding Opportunities

Grants awarded through this request for applications are intended to advance the understanding of autism spectrum disorder through analyses of human postmortem brain tissue donated to the Autism BrainNet collection.
 
The annual budget is between $300,000 and $1,000,000, inclusive of 20 percent indirect costs, for a period of two (2) years.
 
We encourage proposals from multiple investigators only when such collaborations are well justified by the expected benefits to the proposal. For collaborative proposals, the annual budget can exceed the project cap stated above but should not exceed a total of $2,000,000 inclusive of 20 percent indirect costs.

Grants awarded through this RFA are intended to capitalize on the rat as a model system to advance our understanding of the behavioral and circuit neuroscience mechanisms driving autism. This RFA will support a consortium of investigators to collaboratively use SFARI autism rat models to examine the biological basis of complex behaviors and the underlying neural circuits relevant for autism. We welcome applications from individual labs, as well as collaborative applications of up to three (3) principal investigators.

Each lab may request a maximum of $300,000, inclusive of 20 percent indirect costs, for each year of funding over a period of two (2) to three (3) years.

Grants awarded through this RFA are intended to advance our understanding of the genetic basis of ASD and the molecular and cellular consequences of genetic risk, and to provide a foundation for the development of treatments for select genetically defined forms of the condition. Special emphasis is placed on the use of scalable methods, especially as applied to genes that are suitable targets for genetic therapies.

The annual budget is between $200,000 and $400,000, inclusive of 20 percent indirect costs, for a period of two or three years.

Grants awarded through this RFA are intended to produce foundational knowledge about the neurobehavioral differences associated with ASD, which will directly inform the development or refinement of tools needed for translational efforts, such as biomarkers and outcome measures. Special emphasis is placed on objective, quantitative measures that may be used in conjunction with standardized clinical measures and genomic information to better triangulate phenotypic and neurobiological variability within and across individuals with ASD.

The maximum budget is $750,000 or less, inclusive of 20 percent indirect costs, over a period of up to three years.

Grants awarded through this RFA will supplement funding from other agencies for ongoing pregnancy cohorts to broaden biospecimen collection and to extend post-natal family tracking. These cohorts and biospecimen collections can be leveraged in future research to understand the effects of gestational infection and inflammation on autism risk in children.

The maximum budget is $250,000 for projects recruiting at a single site, and $400,000 for projects recruiting at two or more sites.

SFARI Collaborations are a new funding mechanism that will provide substantive and stable funding support to multidisciplinary teams of investigators tackling critical issues in the autism research field. Collaborations will be led by a director who oversees interdisciplinary, synergistic research efforts across multiple laboratories. Investigative groups within a Collaboration will focus on the same conceptually unified topic but will incorporate different scientific disciplines, multiple levels of analysis, and will include a robust data-sharing infrastructure.
 
SFARI Collaborations have a maximum budget of up to $8,000,000, including 20 percent indirect costs, over an initial period of four years, with a possible three-year extension.
 
For our first Collaboration RFA, SFARI solicits applications to investigate sex differences in autism.

Grants awarded through this RFA are intended to provide support for the investigation of key unresolved research questions in autism, particularly those that connect etiology to brain function and behavior. SFARI welcomes risk and novelty in Research Award proposals, but potential impact on the autism research field will be the most important criterion. Competitive applications will have preliminary data or other relevant groundwork that justifies substantial investment on the proposed topic.

The maximum budget is $1,300,000, including indirect costs, over a period of up to four years.

Grants awarded through this request for applications are intended to develop and validate outcome measures that are suitable for use in intervention studies that target the core symptoms of autism spectrum disorder. Such measures should provide objective data with strong psychometric properties, be scalable for use in large, multisite studies, not be unduly burdensome to participants and families, and have evident clinical relevance. They would ideally capture naturalistic rather than laboratory behavior and be applicable to subjects across a wide range of ages and levels of functioning.

We expect to fund several awards through this mechanism. The maximum budget is $300,000 per year, including indirect costs, for up to three years. Higher budgets will be considered, but such budgets must be strongly justified.

SPARK is a SFARI initiative intended to recruit, engage and retain a community of 50,000 individuals with autism, and their family members, in the United States. This research cohort includes children and adults who span the full autism spectrum and individuals of all socio-demographic backgrounds.

Through this RFA, SFARI will add additional clinical sites to its existing clinical site network for the purposes of recruiting SPARK participants. Selected clinical sites will receive funding of up to $200,000/year, including indirect costs, for a maximum of three years.

Grants awarded through this RFA are intended to advance our understanding of the genetic basis of autism. Investigators who are interested in analyzing genomic data in innovative ways from thousands of SPARK families are encouraged to apply.

Available data will include whole-exome and genome-wide genotyping data from approximately 4,500 individuals with autism spectrum disorder (ASD) and their biological parents. Approximately half of these families will also have genomic data from an unaffected sibling. In addition, whole-genome sequencing data will be available from approximately 400 other ASD individuals, plus their biological parents and unaffected siblings. A limited phenotypic dataset for all participants will be available.

We expect to fund several awards in the range of $100,000 (direct costs) for 18 months. Higher budgets will be considered, but we expect such budgets to be strongly justified.